Stock events for AN2 Therapeutics, Inc. (ANTX)
In the past six months, AN2 Therapeutics' stock price has been impacted by several events. The stock price increased after announcing plans to advance oral epetraborole into a Phase 2 study for Polycythemia Vera. Participation in the Leerink Global Healthcare Conference led to a slight decline in stock price. FDA clearance to proceed with a trial of epetraborole in patients with M. abscessus lung disease was followed by a stock price decrease. The company reported its third-quarter 2025 financial results, after which shares declined. Insiders who bought AN2 Therapeutics stock were rewarded as the company's market value increased. Shares of AN2 Therapeutics plunged after the company announced the discontinuation of its study on epetraborole for MAC lung disease due to unsatisfactory efficacy results.
Demand Seasonality affecting AN2 Therapeutics, Inc.’s stock price
Information regarding specific demand seasonality for AN2 Therapeutics' products and services is not available. As a clinical-stage biopharmaceutical company, its primary products are still in development, and its valuation is tied to clinical trial milestones, regulatory approvals, and pipeline advancements rather than seasonal consumer demand.
Overview of AN2 Therapeutics, Inc.’s business
AN2 Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics, operating within the Healthcare sector, specifically in the Biotechnology and Medicinal and Botanical Manufacturing industries. The company utilizes a proprietary boron chemistry platform to create compounds aimed at addressing unmet medical needs in infectious diseases and oncology. Its lead drug candidate, Epetraborole, is in Phase 3 clinical trials for NTM lung disease and is being studied for acute melioidosis, with plans to advance it into a Phase 2 study for Polycythemia Vera. AN2-502998 is in development for chronic Chagas disease, with a Phase 1 study underway and a Phase 2 study planned for 2026. The company also has early and preclinical programs targeting oncology and other infectious diseases.
ANTX’s Geographic footprint
AN2 Therapeutics is headquartered in Menlo Park, California, and has strategic licensing agreements, including one with Brii Biosciences Limited for epetraborole in China, Hong Kong, Taiwan, and Macau. Additionally, AN2 has a collaboration with GSK plc for the development of new therapies for tuberculosis.
ANTX Corporate Image Assessment
AN2 Therapeutics' brand reputation has been influenced by its clinical trial outcomes and stock performance. The discontinuation of the Phase 2/3 study for epetraborole in MAC lung disease led to a substantial drop in stock price. The company has maintained a strong cash position, reaffirming its financial runway into 2028. The stock has received a "Sell" rating from Danelfin's AI model and a "Hold" rating from Zacks Investment Research.
Ownership
AN2 Therapeutics has a diverse ownership structure, including institutional owners and shareholders such as Almitas Capital LLC, Vanguard Group Inc, and Pfizer Inc. Individual insiders, including CEO Eric Easom, CFO Lucy Day, and Stephen Prior, also hold a proportion of the company's shares. Over the past year, insiders have been net buyers of the stock.
